Literature DB >> 15621396

The effects of trauma recall on smoking topography in posttraumatic stress disorder and non-posttraumatic stress disorder trauma survivors.

F Joseph McClernon1, Jean C Beckham, Susannah L Mozley, Michelle E Feldman, Scott R Vrana, Jed E Rose.   

Abstract

Smoking topography was measured in trauma survivors with and without posttraumatic stress disorder (PTSD) after recalling trauma-related and neutral experiences. Analysis of covariance was performed on puff topography and mood measures using nicotine dependence scores and current major depressive disorder as covariates. Puff volumes were higher in the PTSD group than in the non-PTSD group. The PTSD group exhibited stable puff onset intervals while the non-PTSD group exhibited significantly shorter intervals following trauma recall. These findings support a "ceiling effect" hypothesis in which individuals with PTSD perpetually smoke in such a way as to maximize nicotine delivery, possibly reducing the potentially reinforcing effects of increased smoke delivery in negative affect-inducing situations.

Entities:  

Mesh:

Year:  2005        PMID: 15621396     DOI: 10.1016/j.addbeh.2004.05.013

Source DB:  PubMed          Journal:  Addict Behav        ISSN: 0306-4603            Impact factor:   3.913


  19 in total

1.  Enhancing the benefits of written emotional disclosure through response training.

Authors:  Andrea Konig; Alison Eonta; Stephanie R Dyal; Scott R Vrana
Journal:  Behav Ther       Date:  2013-12-27

2.  Smoking Through a Topography Device Diminishes Some of the Acute Rewarding Effects of Smoking.

Authors:  Kathryn C Ross; Laura M Juliano
Journal:  Nicotine Tob Res       Date:  2015-07-25       Impact factor: 4.244

3.  Posttraumatic stress symptoms and tobacco abstinence effects in a non-clinical sample: evaluating the mediating role of negative affect reduction smoking expectancies.

Authors:  Kirsten J Langdon; Adam M Leventhal
Journal:  J Psychopharmacol       Date:  2014-08-20       Impact factor: 4.153

4.  Examining the effects of initial smoking abstinence on response to smoking-related stimuli and response inhibition in a human laboratory model.

Authors:  Matthew P Bradstreet; Stephen T Higgins; F Joseph McClernon; Rachel V Kozink; Joan M Skelly; Yukiko Washio; Alexa A Lopez; Marie A Parry
Journal:  Psychopharmacology (Berl)       Date:  2013-12-15       Impact factor: 4.530

5.  Posttraumatic stress and emotion dysregulation: Relationships with smoking to reduce negative affect and barriers to smoking cessation.

Authors:  Nicole A Short; Mary E Oglesby; Amanda M Raines; Michael J Zvolensky; Norman B Schmidt
Journal:  Compr Psychiatry       Date:  2015-05-27       Impact factor: 3.735

Review 6.  Smoking, traumatic event exposure, and post-traumatic stress: a critical review of the empirical literature.

Authors:  Matthew T Feldner; Kimberly A Babson; Michael J Zvolensky
Journal:  Clin Psychol Rev       Date:  2006-10-10

7.  Predictors and sequelae of smoking topography over the course of a single cigarette in adolescent light smokers.

Authors:  Jennifer C Veilleux; Jon D Kassel; Adrienne J Heinz; Ashley Braun; Margaret C Wardle; Justin Greenstein; Daniel P Evatt; Megan Conrad
Journal:  J Adolesc Health       Date:  2011-02       Impact factor: 5.012

8.  Reasons for quitting smoking prior to a self-quit attempt among smokers with and without posttraumatic stress disorder or other anxiety/mood psychopathology.

Authors:  Erin C Marshall; Anka A Vujanovic; Amanda Kutz; Laura Gibson; Teresa Leyro; Michael J Zvolensky
Journal:  Am J Addict       Date:  2009 Jul-Aug

9.  Association between trauma exposure and smoking in a population-based sample of young adults.

Authors:  Miguel E Roberts; Bernard F Fuemmeler; F Joseph McClernon; Jean C Beckham
Journal:  J Adolesc Health       Date:  2008-03       Impact factor: 5.012

10.  24-h smoking abstinence potentiates fMRI-BOLD activation to smoking cues in cerebral cortex and dorsal striatum.

Authors:  F Joseph McClernon; Rachel V Kozink; Avery M Lutz; Jed E Rose
Journal:  Psychopharmacology (Berl)       Date:  2008-12-24       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.